AnaptysBio (NASDAQ:ANAB) CFO Dennis Mulroy Sells 10,000 Shares

by · The Markets Daily

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) CFO Dennis Mulroy sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $50.00, for a total value of $500,000.00. Following the sale, the chief financial officer owned 9,401 shares of the company’s stock, valued at approximately $470,050. This represents a 51.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Dennis Mulroy also recently made the following trade(s):

  • On Tuesday, December 16th, Dennis Mulroy sold 15,725 shares of AnaptysBio stock. The stock was sold at an average price of $44.85, for a total transaction of $705,266.25.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB traded down $0.29 during midday trading on Tuesday, hitting $50.04. 406,939 shares of the company’s stock were exchanged, compared to its average volume of 692,903. AnaptysBio, Inc. has a 12 month low of $12.21 and a 12 month high of $51.43. The company has a market cap of $1.39 billion, a PE ratio of -17.74 and a beta of 0.28. The stock has a 50 day moving average price of $39.15 and a 200-day moving average price of $29.22.

AnaptysBio (NASDAQ:ANAB – Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, beating the consensus estimate of ($1.06) by $1.58. The business had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. On average, analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its board has authorized a share buyback plan on Friday, November 21st that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

ANAB has been the topic of a number of analyst reports. Truist Financial lifted their price objective on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a report on Monday, November 10th. Barclays decreased their price objective on shares of AnaptysBio from $70.00 to $55.00 and set an “overweight” rating for the company in a research note on Wednesday, December 17th. Stifel Nicolaus reduced their target price on AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Finally, Wedbush reissued an “outperform” rating and issued a $50.00 price objective on shares of AnaptysBio in a research report on Monday, November 24th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $55.40.

Read Our Latest Stock Analysis on ANAB

Institutional Trading of AnaptysBio

Hedge funds have recently made changes to their positions in the company. Larson Financial Group LLC grew its stake in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 473 shares during the period. Bessemer Group Inc. lifted its holdings in AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares during the period. Osaic Holdings Inc. increased its stake in shares of AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,326 shares in the last quarter. Finally, Covestor Ltd raised its position in shares of AnaptysBio by 131,540.0% in the third quarter. Covestor Ltd now owns 6,582 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 6,577 shares during the period.

AnaptysBio Company Profile

(Get Free Report)

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

Featured Stories